Evermay Wealth Management LLC Decreases Holdings in Pfizer Inc. (PFE)
Evermay Wealth Management LLC cut its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.8% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 48,543 shares of the biopharmaceutical company’s stock after selling 4,700 shares during the quarter. Pfizer accounts for about 0.8% of Evermay Wealth Management LLC’s investment portfolio, making the stock its 13th largest holding. Evermay Wealth Management LLC’s holdings in Pfizer were worth $1,733,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also made changes to their positions in the business. Shine Investment Advisory Services Inc. acquired a new stake in shares of Pfizer during the 2nd quarter valued at about $102,000. Mckinley Capital Management LLC Delaware acquired a new stake in shares of Pfizer during the 2nd quarter valued at about $103,000. D. Scott Neal Inc. lifted its holdings in shares of Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 504 shares during the last quarter. Herndon Capital Management LLC acquired a new stake in shares of Pfizer during the 2nd quarter valued at about $120,000. Finally, Lipe & Dalton lifted its holdings in shares of Pfizer by 6.9% during the 2nd quarter. Lipe & Dalton now owns 4,626 shares of the biopharmaceutical company’s stock valued at $155,000 after buying an additional 300 shares during the last quarter. Hedge funds and other institutional investors own 69.75% of the company’s stock.
Pfizer Inc. (NYSE PFE) opened at $36.21 on Wednesday. The company has a quick ratio of 1.15, a current ratio of 1.43 and a debt-to-equity ratio of 0.56. Pfizer Inc. has a one year low of $30.90 and a one year high of $37.35. The firm has a market capitalization of $215,419.95, a P/E ratio of 22.35, a P/E/G ratio of 2.55 and a beta of 1.01.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, October 31st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.65 by $0.02. The company had revenue of $13.17 billion for the quarter, compared to the consensus estimate of $13.17 billion. Pfizer had a return on equity of 25.41% and a net margin of 18.69%. The company’s revenue for the quarter was up .9% on a year-over-year basis. During the same period in the previous year, the business posted $0.61 EPS. research analysts predict that Pfizer Inc. will post 2.59 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 1st. Shareholders of record on Friday, February 2nd will be given a $0.34 dividend. This is an increase from Pfizer’s previous quarterly dividend of $0.32. This represents a $1.36 annualized dividend and a yield of 3.76%. The ex-dividend date of this dividend is Thursday, February 1st. Pfizer’s payout ratio is currently 79.01%.
Pfizer declared that its Board of Directors has approved a stock buyback program on Monday, December 18th that allows the company to repurchase $10.00 billion in outstanding shares. This repurchase authorization allows the biopharmaceutical company to repurchase shares of its stock through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its stock is undervalued.
PFE has been the subject of several research reports. BMO Capital Markets set a $37.00 price target on Pfizer and gave the company a “buy” rating in a report on Tuesday, October 10th. ValuEngine upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Friday, October 6th. Zacks Investment Research downgraded Pfizer from a “buy” rating to a “hold” rating in a research note on Wednesday, October 11th. Deutsche Bank set a $38.00 price objective on Pfizer and gave the company a “buy” rating in a research note on Wednesday, October 11th. Finally, Morgan Stanley raised Pfizer from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $35.00 to $39.00 in a research note on Wednesday, September 20th. Two research analysts have rated the stock with a sell rating, six have issued a hold rating and thirteen have issued a buy rating to the stock. Pfizer presently has an average rating of “Buy” and an average price target of $38.77.
In other Pfizer news, insider Alexander R. Mackenzie sold 14,700 shares of Pfizer stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total value of $518,910.00. Following the transaction, the insider now directly owns 117,432 shares of the company’s stock, valued at approximately $4,145,349.60. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, EVP Alexander R. Mackenzie sold 7,350 shares of Pfizer stock in a transaction that occurred on Monday, October 2nd. The stock was sold at an average price of $35.65, for a total value of $262,027.50. Following the completion of the transaction, the executive vice president now directly owns 117,432 shares in the company, valued at $4,186,450.80. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 36,800 shares of company stock worth $1,327,248. Company insiders own 0.06% of the company’s stock.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with Analyst Ratings Network's FREE daily email newsletter.